ATE179616T1 - Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet - Google Patents

Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet

Info

Publication number
ATE179616T1
ATE179616T1 AT94926660T AT94926660T ATE179616T1 AT E179616 T1 ATE179616 T1 AT E179616T1 AT 94926660 T AT94926660 T AT 94926660T AT 94926660 T AT94926660 T AT 94926660T AT E179616 T1 ATE179616 T1 AT E179616T1
Authority
AT
Austria
Prior art keywords
antagonist
humoral immunity
prolonged suppression
antigen
suppression
Prior art date
Application number
AT94926660T
Other languages
English (en)
Inventor
Randolph J Noelle
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE179616(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Application granted granted Critical
Publication of ATE179616T1 publication Critical patent/ATE179616T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT94926660T 1993-09-02 1994-09-02 Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet ATE179616T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Publications (1)

Publication Number Publication Date
ATE179616T1 true ATE179616T1 (de) 1999-05-15

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94926660T ATE179616T1 (de) 1993-09-02 1994-09-02 Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet

Country Status (14)

Country Link
EP (1) EP0742721B1 (de)
JP (1) JP2840131B2 (de)
CN (1) CN1137726C (de)
AT (1) ATE179616T1 (de)
AU (3) AU7643094A (de)
DE (1) DE69418349T2 (de)
DK (1) DK0742721T3 (de)
ES (1) ES2134954T3 (de)
FI (1) FI106927B (de)
GR (1) GR3030762T3 (de)
IL (1) IL110852A (de)
NO (1) NO321037B1 (de)
NZ (1) NZ273208A (de)
WO (1) WO1995006480A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897983B1 (de) * 1991-10-25 2003-05-07 Immunex Corporation Antikörper gegen CD40-L
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU655349B2 (en) * 1992-02-17 1994-12-15 Kenji Nakamura An antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
GR3030762T3 (en) 1999-11-30
DE69418349D1 (de) 1999-06-10
JP2840131B2 (ja) 1998-12-24
FI960979A (fi) 1996-04-30
NO321037B1 (no) 2006-03-06
EP0742721A1 (de) 1996-11-20
AU734853B2 (en) 2001-06-21
NZ273208A (en) 2000-12-22
NO960863D0 (no) 1996-03-01
FI960979A0 (fi) 1996-03-01
DK0742721T3 (da) 1999-11-01
JPH09502184A (ja) 1997-03-04
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
AU7643094A (en) 1995-03-22
AU2004240180B2 (en) 2007-08-09
ES2134954T3 (es) 1999-10-16
IL110852A0 (en) 1994-11-28
FI106927B (fi) 2001-05-15
IL110852A (en) 1999-05-09
CN1137726C (zh) 2004-02-11
AU1422099A (en) 1999-04-01
CN1137758A (zh) 1996-12-11
EP0742721B1 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
ATE179616T1 (de) Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
DE122010000016I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
DE60043708D1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
FI940335A0 (fi) Sytotoksisten T-lymfosyyttivasteiden indusointi
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
NL930133I1 (nl) Vaccin tegen hepatitis B virus werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin
AU6616301A (en) Modification of hepatitis b core antigen
ATE331798T1 (de) Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
CA2089753A1 (en) Interleukin-2-leukotoxin gene fusions and uses therefor
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
NZ502144A (en) Multi-subtype FIV vaccines
DE3875043T2 (de) Immunogenes produkt, erhalten durch expression in einer rekombinanten hefe, und verfahren zu seiner reinigung.
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
PT1021196E (pt) Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio
DK364286A (da) Varicella-zoster virus (vzv) ga, gb og gc glycoproteiner i renset, ikke-denatureret, serologisk aktiv form og fremgangsmaade til proevning for tilstedevaerelsen af antistoffer over for disse
NO870123L (no) Mastittvaksine.
AU6136694A (en) Methods for generating broadly neutralizing anti-hiv antibodies and antigens capable of eliciting same
DK41885A (da) 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
EP0312839A3 (en) Method for the preparation of an inducer of non-specific immunity
AUPQ661600A0 (en) A nucleic acid construct and methods related thereto
DE3750642D1 (de) Verfahren und Zusammensetzungen betreffend regressions-assoziierte Antigene.
MY103035A (en) Novel proteins and method of producing same
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
ATE287538T1 (de) Verfahren zur immunchemischen quantifizierung von inaktivierten, immunreaktiven antigenen
GB2114288B (en) Method for the detection of malaria antigens in human blood

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked